Please create a presentation entirely in English—titled "Systemic Therapy for Moderate-to-Severe Atopic Dermatitis in Children: Real-World Evidence and Clinical Implication"—for an international academic symposium on atopic dermatitis. The presentation should be based on my previously published article (see below attached file) and incorporate high-quality international literature from recent years. It requires a clear logical flow, comprehensive and in-depth content, high-quality visuals, and an aesthetically pleasing, well-organized layout.
Please create a presentation entirely in English—titled "Systemic Therapy for Moderate-to-Severe Atopic Dermatitis in Children: Real-World Evidence and Clinical Implication"—for an international academic symposium on atopic dermatitis. The presentation should be based on my previously published article (see below attached file) and incorporate high-quality international literature from recent years. It requires a clear logical flow, comprehensive and in-depth content, high-quality visuals, and an aesthetically pleasing, well-organized layout.
Created using ChatSlide
This study explores the significance of systemic therapy in early-childhood atopic dermatitis (AD), focusing on Dupilumab's role in targeting IL-4Rα-driven type 2 inflammation. Key findings include a 70.8% EASI-75 response at week 16 and significant improvements in pruritus. Additionally, PON2 and PRDX1 are identified as promising biomarkers for response stratification, with AUC values of 0.778 and 0.764, respectively. These insights pave the way for future clinical implications and research...